Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals

BeiGene to Terminate Partnership with NewBridge Pharmaceuticals for MENA Region

Fineline Cube Jun 14, 2024

BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a leading biopharmaceutical company based in China, has...

Company Deals

Ethypharm Expands in China’s IBD Market with Acquisition of Mesalazine Suppository

Fineline Cube Jun 14, 2024

Ethypharm, a France-based pharmaceutical company, has announced that its Chinese subsidiary, Shanghai Ethypharmaceuticals Ltd, has...

Company Deals

Sihuan’s Xuanzhu Biopharmaceutical Strikes Licensing Deal with Livzon Pharmaceutical for Fadanafil

Fineline Cube Jun 14, 2024

Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has declared that its subsidiary, Xuanzhu Biopharmaceutical Co.,...

Company Drug

CStone Pharmaceuticals Gets NMPA Green Light for Local Production of Gavreto

Fineline Cube Jun 14, 2024

CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has announced that it...

Company Drug

Innovent Biologics’ IBI363 Shows Promising Results in Phase Ia/Ib Trial for Advanced Solid Tumors

Fineline Cube Jun 14, 2024

Innovent Biologics Inc., (HKG: 1801), a leading biopharmaceutical company based in China, has announced the...

Company Deals

Ronovo Surgical Secures Over RMB 300 Million in Series B to Globalize Surgical Robot

Fineline Cube Jun 14, 2024

Shanghai-based surgical robotics specialist, Ronovo Surgical, has reportedly raised over RMB 300 million (USD 41.3...

Company Deals Drug

Cellbri Bio Secures Nearly RMB 200 Million in Series B Financing to Boost CGT Commercialization

Fineline Cube Jun 14, 2024

Shenzhen Cellbri Bio-Innovation Technology Co., Ltd, a prominent player in China’s cell and gene therapy...

Company Deals Medical Device

Zhejiang Dian Diagnostics Partners with Quest Diagnostics to Advance Alzheimer’s Disease Blood Tests

Fineline Cube Jun 14, 2024

Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244), a leading diagnostics company based in China, has...

Company Drug

Apeloa Pharmaceutical Partners with Beijing Highthink for CRO Services on Semaglutide Generic

Fineline Cube Jun 14, 2024

Apeloa Pharmaceutical Co., Ltd (SHE: 000739), a China-based pharmaceutical company, has forged a strategic partnership...

Company Deals

GSK Partners with Ochre Bio to Access Liver Data for Hepatology Therapy Development

Fineline Cube Jun 14, 2024

GlaxoSmithKline (GSK; NYSE: GSK), a UK-based pharmaceutical giant, has entered into an agreement with fellow...

Company Drug

Pfizer’s Gene Therapy for Duchenne Muscular Dystrophy Misses Late-Stage Trial Endpoints

Fineline Cube Jun 14, 2024

Pfizer Inc. (NYSE: PFE) has announced that a late-stage clinical trial for its investigational gene...

Company Drug

AstraZeneca’s Farxiga Receives FDA Approval for Pediatric Type-2 Diabetes Treatment

Fineline Cube Jun 14, 2024

The US Food and Drug Administration (FDA) has granted regulatory approval to AstraZeneca (AZ; NASDAQ:...

Company Drug

Amgen’s Prolia Secures NMPA Approval for Treating Glucocorticoid-Induced Osteoporosis in High-Risk Patients

Fineline Cube Jun 14, 2024

Biopharmaceutical giant Amgen has received marketing approval from China’s National Medical Products Administration (NMPA) for...

Policy / Regulatory

NHSA Seeks Public Input on National Reimbursement Drug List Adjustments

Fineline Cube Jun 14, 2024

The National Healthcare Security Administration (NHSA) has unveiled the adjustment plan for the National Reimbursement...

Company Drug

Eli Lilly’s Baqsimi Gains NMPA Approval for Diabetes Hypoglycemia Treatment

Fineline Cube Jun 13, 2024

The National Medical Products Administration (NMPA) in China has granted approval to Eli Lilly &...

Company Deals

Chia Tai Tianqing and China Resource Medicine Commercial Holdings Join Forces for Pharmaceutical Industry Expansion

Fineline Cube Jun 13, 2024

Chia Tai Tianqing, a renowned name in the Chinese healthcare industry, has forged a strategic...

Company Drug

Boehringer Ingelheim’s Survodutide Earns Breakthrough Designation for MASH Treatment in China

Fineline Cube Jun 13, 2024

Boehringer Ingelheim (BI), the German pharmaceutical colossus, has declared that it has been granted Breakthrough...

Company Drug

Innovent Biologics’ CLDN18.2-Targeted ADC IBI343 Earns FDA Fast-Track Status

Fineline Cube Jun 13, 2024

Innovent Biologics Inc. (HKG: 1801), a leading biopharmaceutical company based in China, has announced that...

Company Drug

Zelgen Biopharmaceuticals’ Jacktinib Meets Primary Endpoint in Severe Alopecia Areata Trial

Fineline Cube Jun 13, 2024

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...

Company Drug

Joincare Pharmaceutical Receives NMPA Approval for Generic Seretide

Fineline Cube Jun 13, 2024

Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380), a leading pharmaceutical company based in China,...

Posts pagination

1 … 369 370 371 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.